Abstract
Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.
Highlights
Acute myeloid leukemia (AML), the most common type of adult leukemia, is characterized by the accumulation of cloning and differentiation arrest in the bone marrow and blood
To assess the performance of chemerin expression as a marker, receiver operating characteristic (ROC) curves were constructed to analyze the sensitivity of this marker in distinguishing acute myeloid leukemia (AML) patients from healthy controls. (AUC=0.611, 95% CI: 0.4900.732, P=0.042, Figure 2)
With a cut-off value of 0.0826, the sensitivity and the specificity were 79% and 54%, respectively. These results demonstrated that chemerin expression might serve as a valuable biomarker for AML diagnosis
Summary
Acute myeloid leukemia (AML), the most common type of adult leukemia, is characterized by the accumulation of cloning and differentiation arrest in the bone marrow and blood. Another study showed that the expression of chemerin was overexpressed in colorectal cancer [16], squamous cell carcinoma of the oral tongue [17], gastric cancer [18] correlated with tumor angiogenesis and poor clinical outcomes of patients and upregulatedin grade III/IV glioma tissues compared with grade II ones or brain samples from patients with epilepsy [19]. These surveys demonstrate that the dysregulation of chemerin may have an important impact on tumorigenesis and progression, but the expression and roles of chemerin in AML remain unclear
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
